Kenneth W Dobie

USPTO Granted Patents = 76 (Patent Applications = 11)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 12)

Average Co-Inventor Count = 2.8

ph-index = 16

Forward Citations = 1,422(Granted Patents)

Forward Citations (Not Self Cited) = 1,387(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Carlsbad, CA (US) (2008 - 2012)
San Diego, CA (US) (2012)
Del Mar, CA (US) (2003 - 2018)
Solana Beach, CA (US) (2016 - 2022)

Company Filing History:

68 out of 1,035

Isis Pharmaceuticals, Inc.

patents

7 out of 17

Antisense Therapeutics Limited

patents

5 out of 270

Ionis Pharmaceuticals, Inc.

patents

4. 2 out of 4,442

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2003-2022

Loading Chart...

76 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11225664 - Modulation of angiopoietin-like 3 expression (2022-01-18),

2. 10526604 - Modulation of nuclear-retained RNA (2020-01-07),

3. 9856473 - Compositions and methods for modulation of LMNA expression (2018-01-02),

4. 9624496 - Modulation of apolipoprotein C-III expression (2017-04-18),

5. 9476051 - Antisense modulation of superoxide dismutase 1, soluble expression (2016-10-25),

6. 9157082 - Modulation of apolipoprotein CIII (ApoCIII) expression (2015-10-13),

7. 9139831 - Modulation of angiopoietin-like 3 expression (2015-09-22),

8. 8993529 - Antisense modulation of superoxide dismutase 1, soluble expression (2015-03-31),

9. 8921331 - Methods for slowing familial ALS disease progression (2014-12-30),

10. 8883997 - Modulation of diacylglycerol acyltransferase 2 expression (2014-11-11),

11. 8865884 - Antisense modulation of kinesin-like 1 expression (2014-10-21),

12. 8853178 - Antisense modulation of PTP1B expression (2014-10-07),

13. 8791088 - Compositions and methods for modulation of LMNA expression (2014-07-29),

14. 8778900 - Modulation of eIF4E-BP1 expression (2014-07-15),

15. 8765700 - Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions (2014-07-01),

Title: A Pioneer in Biomedical Innovation: Kenneth W Dobie

Introduction:

Kenneth W Dobie, a visionary inventor in the field of biomedical research, hails from Del Mar, CA (US). With an impressive 76 patents to his name, Dobie has made groundbreaking contributions to the healthcare industry.

Latest Patents:

Among his recent patents, Dobie's work on "Modulation of Angiopoietin-Like 3 Expression" stands out. This patent introduces innovative methods, compounds, and compositions aimed at reducing ANGPTL3 expression and addressing cardiovascular and metabolic diseases. Additionally, his patent on "Modulation of Nuclear-Retained RNA" showcases his commitment to developing treatments for diseases associated with nuclear-retained RNA.

Career Highlights:

Dobie's career has been marked by his tenure at notable companies such as Isis Pharmaceuticals, Inc. and Antisense Therapeutics Limited. His expertise and relentless pursuit of innovation have propelled him to the forefront of biomedical research.

Collaborations:

Throughout his career, Dobie has collaborated with esteemed professionals in the field. Notably, he has worked alongside accomplished individuals like Sanjay Bhanot and Susan M Freier, further enriching the impact of his research and inventions.

Conclusion:

Kenneth W Dobie's inventive spirit and remarkable contributions have revolutionized the biomedical landscape. His relentless dedication to improving healthcare outcomes underscores his status as a pioneer in the field of innovation.

This text is generated by artificial intelligence and may not be accurate.